1950
DOI: 10.1172/jci102340
|View full text |Cite
|
Sign up to set email alerts
|

Mucolytic Enzyme Systems. X. Serum Hyaluronidase Inhibitor in Liver Disease 1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

1952
1952
2009
2009

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(3 citation statements)
references
References 6 publications
(5 reference statements)
0
3
0
Order By: Relevance
“…Furthermore, a number of clinical studies report increased levels of inhibitor in the serum of patients with cancer, liver disease and dermatological disorders (Grais and Glick, 1948;Snively and Glick, 1950;Newman et al, 1955;Kolarova, 1975). Based on these studies, Mio et al (2000) purified a high molecular mass (120 kDa), thermolabile glycoprotein hyaluronidase inhibitor from mouse serum.…”
Section: Hyaluronidase Inhibitorsmentioning
confidence: 99%
“…Furthermore, a number of clinical studies report increased levels of inhibitor in the serum of patients with cancer, liver disease and dermatological disorders (Grais and Glick, 1948;Snively and Glick, 1950;Newman et al, 1955;Kolarova, 1975). Based on these studies, Mio et al (2000) purified a high molecular mass (120 kDa), thermolabile glycoprotein hyaluronidase inhibitor from mouse serum.…”
Section: Hyaluronidase Inhibitorsmentioning
confidence: 99%
“…The presence of inhibitor was justified by a number of clinical studies that report increased levels of inhibitor in the serum of patients with cancer, liver and dermatological disorders [101][102][103][104]. Based on these studies, Mio et al [105] isolated a high molecular mass (120 kDa), thermolabile glycoprotein HAase inhibitor from mouse serum.…”
Section: Proteinsmentioning
confidence: 99%
“…The first studies documenting the existence of a circulating inhibitor of hyaluronidase were published from 1946 to 1949 (21)(22)(23). These studies were followed by clinical reports that increased inhibitor levels occur in the sera of patients with cancer (24 -26), liver disease (27), and dermatological disorders (28). These inhibitors were high molecular mass thermolabile glycoproteins (29) requiring magnesium ion for full activity (30).…”
Section: Hyaluronan (Ha)mentioning
confidence: 99%